
July 12, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

Canagliflozin may be cost-effective option for type 2 diabetes with diet, exercise

In adult patients with type 2 diabetes inadequately controlled on metformin monotherapy, canagliflozin (Invokana) 100 mg and 300 mg reduced relative risk for myocardial infarction and congestive heart failure, as compared to sitagliptin 100 mg, according a health economic simulation analysis presented at the American Diabetes Association meeting. Read more

Study: Childhood vaccines are safe, low risk

There are some risks associated with some childhood vaccinations, but overall the evidence shows that vaccines are very safe, according a new study. Read more

#icymi